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Summary
Forkhead box P3 (FoxP3)1 regulatory T cells (Tregs) are functionally
deficient in systemic lupus erythematosus (SLE), characterized by reduced
surface CD25 [the interleukin (IL)-2 receptor alpha chain]. Low-dose IL-2
therapy is a promising current approach to correct this defect. To elucidate
the origins of the SLE Treg phenotype, we studied its role through
developmentally defined regulatory T cell (Treg) subsets in 45 SLE patients,
103 SLE-unaffected first-degree relatives and 61 unrelated healthy control
subjects, and genetic association with the CD25-encoding IL2RA locus.
We identified two separate, uncorrelated effects contributing to Treg CD25.
(1) SLE patients and unaffected relatives remarkably shared CD25 reduction
versus controls, particularly in the developmentally earliest CD41 FoxP31
CD45RO–CD311 recent thymic emigrant Tregs. This first component effect
influenced the proportions of circulating CD41FoxP3high CD45RO1
activated Tregs. (2) In contrast, patients and unaffected relatives differed
sharply in their activated Treg CD25 state: while relatives as control subjects
up-regulated CD25 strongly in these cells during differentiation from naive
Tregs, SLE patients specifically failed to do so. This CD25 up-regulation
depended upon IL2RA genetic variation and was related functionally to the
proliferation of activated Tregs, but not to their circulating numbers. Both
effects were found related to T cell IL-2 production. Our results point to (1)
a heritable, intrathymic mechanism responsible for reduced CD25 on early
Tregs and decreased activation capacity in an extended risk population,
which can be compensated by (2) functionally independent CD25 up-
regulation upon peripheral Treg activation that is selectively deficient in
patients. We expect that Treg-directed therapies can be monitored more
effectively when taking this distinction into account.
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Introduction
Systemic lupus erythematosus (SLE) is an autoimmune
disease characterized by combined adaptive and innate-
immune aberrations that can affect diverse organs particu-
larly through immune complex-mediated tissue damage.
However, the aetiology and pathogenic processes of SLE
are not understood fully. Both genetic and environmental
factors contribute to immune dysfunction [1]. In the asso-
ciated breakdown of tolerance, T cells play a key role by
amplifying autoimmune responses [2]. Many abnormalities
of T lymphocytes have been described in SLE patients,
including dysregulated intracellular signal transduction
and imbalanced cytokine production [3], which influence
B cell function and autoantibody production. While SLE T
cells help B cells to generate the pathogenic autoantibodies,
they also fail characteristically to produce sufficient
amounts of interleukin (IL)-2 [4].
Limited amounts of IL-2 affect primarily forkhead box
P3 (FoxP3)1 regulatory T cells (Tregs), which depend
greatly upon this cytokine for their development, survival
and function [5]. Recently, the importance of deficient IL-2
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production and its effects mediated by Tregs was supported
strongly by the clinical efficacy of low-dose IL-2 therapy in
SLE, shown to boost Treg activity and to re-establish toler-
ance mechanisms that can counter autoimmunity and
improve patients’ clinical outcome [6,7]. This is in line
with reported Treg aberrations in SLE [8,9], despite some
discrepancies in previous studies: while some authors had
reported decreased circulating Treg proportions in active
disease [10–15], others had found them normal [16–19] or
even increased [20–24]. These divergences, however, can be
explained largely by a population of aberrant CD41 T cells
expressing FoxP3 but low or no CD25, which is almost
non-existent in healthy individuals but present in signifi-
cant numbers in SLE [19,25–27] where it ‘dissociates’
FoxP3 from CD25-based Treg quantitation. These CD25-
deficient cells have a natural Treg phenotype of deficient
functionality [25], and their frequencies correlate with dis-
ease activity and (inversely) with Treg suppressive capacity
[28]. The hypothesis that they indicate an SLE-specific Treg
dysfunction is consistent with earlier reports of functional
Treg defects [15,16,29].
Human FoxP31 cells have been subdivided into three
functionally and phenotypically distinct subsets [30]: naive
Tregs (FoxP3
1CD45RA1), short-lived and highly suppres-
sive activated Tregs ( FoxP3
highCD45RA–) and another
CD45RA– population with low FoxP3 expression and defi-
cient or absent functionality (FoxP3low). Activated Tregs are
derived generally from naive Tregs [31], while the FoxP3
low
subset can, in part, represent transient FoxP3 expression by
non-regulatory T helper (Th) cells [30]. While it was
speculated that this could also apply to atypical CD25-
deficient Tregs in SLE [27], it is now clear that it is not the
case. In fact, no evidence was found for a role of transient
FoxP3 expression in SLE, as not only FoxP3highCD25high
but also CD25low/negative activated Tregs bear strong markers
of bona-fide, probably thymus-derived Tregs [7,32], i.e.
high levels of Helios expression [33,34], and fully demethy-
lated FoxP3–TSDR [35]. Therefore, Tregs in SLE apart from
FoxP3low cells can basically be seen as belonging to a lineage
derived from naive Tregs.
In complex diseases, the study of unaffected relatives can
reveal shared heritable factors that probably contribute to
pathogenesis, and separate them from divergent pheno-
types which are secondary to disease manifestation. Unaf-
fected relatives of SLE patients frequently present IgG
autoantibodies of SLE-associated specificity [36], although
they rarely develop the disease. We have reported previ-
ously that these relatives, in contrast to unrelated healthy
controls or the patients themselves, showed consistent pos-
itive correlations of SLE-associated specific IgG with
CD251 Tregs [37]. This suggested a compensatory role of
Tregs with the capacity to control autoantibody-related
pathogenic effects, eventually allowing the unaffected rela-
tives to avoid manifest disease.
In order to elucidate more clearly the SLE Treg phenotype,
which also plays a role in intravenous immunoglobulin
(i.v.Ig) therapy [38], and the Treg-mediated compensation in
unaffected relatives, we have now studied the reduced sur-
face CD25 quantitatively in the three classic Treg subsets [30]
and tracked it through developmental stages making use of
their lineage property. Our results point to two separate con-
tributing effects: (a) a shared, probably intrathymic CD25
reduction that leads to a decreased activation capacity in
developmentally early Tregs, compensated in unaffected rela-
tives but not patients by (b) a functionally independent
CD25 up-regulation that occurs upon peripheral Treg
activation.
Materials and methods
Patients and sampling
Peripheral blood samples were collected from 102 SLE
patients who fulfilled current American College of Rheu-
matology (ACR) criteria for SLE, 197 first-degree relatives
of the patients from a total of 94 families and 141 unrelated
healthy controls upon signed informed consent. Relatives
were subjected to a survey questionnaire to rule out clinical
SLE, and three who were, in fact, diagnosed with SLE either
before or subsequent to our collection were excluded from
the study that therefore included 194 unaffected relatives at
the end. SLE patients underwent a detailed clinical charac-
terization, the results of which are summarized in Table 1.
Approval was obtained from the Ethics Committees of
Hospital Geral de Santo Antonio, Centro Hospitalar do
Porto (Porto), Centro Hospitalar Lisboa Norte/Santa
Maria, Centro Hospitalar Lisboa Ocidental and Hospital de
Curry Cabral, Centro Hospitalar de Lisboa Central
(Lisbon).
Peripheral blood samples (30 ml per individual) were
collected into Vacutainer cell preparation tubes with
sodium citrate [Becton-Dickinson (BD), Franklin Lakes,
NJ, USA], and plasma and peripheral blood mononuclear
cells (PBMCs) were isolated by centrifugation, according to
the manufacturer’s protocol.
Flow cytometry
For flow cytometric analysis, PBMC were washed twice in
phosphate-buffered saline (PBS) containing 2% fetal calf
serum (FCS) prior to incubation with antibodies and 106
cells were incubated for 30 min on ice with anti-CD4-
Pacific Orange (Invitrogen, Carlsbad, CA, USA; clone
S3.5), anti-CD31-Pacific Blue (exBio, Vestev, Czech Repub-
lic; clone MEM-05) anti-CD127-allophycocyanin (APC)/
eFluor780 (eBioscience, San Jose, CA, USA; clone
eBioRDR5), anti-CD25-phycoerythrin (PE) (BD; clone
2A3), anti-CD39-PE/cyanin 7 (Cy7) (eBioscience; clone
A1) and anti-CD45RO-peridinin chlorophyll (PerCP)
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(Invitrogen; clone UCHL1). For subsequent intracellular
staining, cells were washed again, fixed and permeabilized
using a fix/perm kit (eBioscience) and stained for intracel-
lular FoxP3 and Ki67 with anti-FoxP3-APC (eBioscience;
clone PCH101) and anti-Ki67-fluorescein isothiocyanate
(FITC) (BD; clone 35/Ki-67). Fluorescence was assessed
using a Cyan ADP flow cytometer and analysed using
FlowJo software (TreeStar Inc., Ashland, OR, USA. Adapt-
ing the scheme of Miyara et al. [30], we distinguished three
FoxP31 subsets: CD45RO– FoxP31 naive Tregs, CD45RO
1
FoxP3high activated Tregs and CD45RO
1 FoxP3low cells
(depicted in Fig. 1). To keep subset definitions objective
and unbiased, we used identical absolute distances on the
log-fluorescence scale between the lower boundaries of
FoxP3low and FoxP3high subset gates in all samples. To mea-
sure surface CD25, the PE median fluorescence intensity
(MFI) was quantified. Analysis of this property was
restricted to samples collected within a defined time-period
where parallel assessment of PE-coupled cytometric beads
validated the longitudinal commensurateness of MFI meas-
ures (45 SLE patients, 103 unaffected relatives and 61 con-
trols). Also, CD127 staining was used principally for
quality control (not gating; however, in 10 samples with
visible separate CD127high FoxP31 populations, these were
gated out). Treg CD127 MFIs were always below 80%
(median 5 44%) of the MFIs measured in CD41 FoxP3–
conventional Th in the same sample with a single excep-
tion, where low CD127 as it characterizes Tregs was also
found on the Th cells.
Cell culture
Isolated 106 PBMC were stimulated with phorbol myristate
acetate (PMA) (25 ng/ml) and ionomycin (1 lg/ml) for 6 h
at 378C in RPMI-1640 medium containing 10% FCS and
10 lg/ml brefeldin A. Immediately after stimulation, the
cells were stained with anti-CD3-APC/Cy7 (BioLegend;
clone HIT3a), anti-CD4-PerCP (BioLegend; clone RPA-
T4), anti-CD8-PE/Cy7 (eBioscience; clone RPA-T8) and
anti-CD45RO-Pacific Blue (BioLegend; clone UCHL1).
Subsequently, cells were fixed and permeabilized using
Cytofix/Cytoperm (BD), washed and stained for intracellu-
lar IL-2 in Perm buffer with anti-IL-2-APC [eBioscience;
clone MQ1–17H12, in parallel with interferon (IFN)-g and
tumour necrosis factor (TNF)-a], assessed cytometrically
with a fluorescence activated cell sorter (FACS)Canto II
cytometer and analysed using FlowJo software (TreeStar,
Inc.).
IL2RA (CD25) genotyping
Genomic DNA was extracted from peripheral blood cells
by standard salting-out. Genotyping of 25 locus-spanning
single nucleotide polymorphisms (SNPs) (Table 2) was per-
formed on the SequenomTM platform, as described previ-
ously [37]. All 25 typed SNPs passed quality control with
call rates above 85% and Hardy–Weinberg equilibrium
(P> 001) was fulfilled within the control subjects.
Data analysis
Data were analysed with Igor Pro software (WaveMetrics,
Lake Oswego, OR, USA) and a statistical package that we
have developed for it (also see [36–38]). Pairwise group
comparisons of continuous variables were performed by the
distribution-independent Mann–Whitney test. Our statistical
approach was to compare patients and unaffected relatives
separately to a control group, followed by within-group anal-
ysis. We did not make all possible groupwise comparisons,
Table 1. General and clinical characteristics
1. SLE patients Total: 102
Gender Male: 8%; female: 92%
Age Median: 405 years;
range 21–73 years
Time of SLE affection Median: 10 years;
range: 0–46 years
Actual disease activity
(SLEDAI-2k)
Median: 2; range: 0–30
Clinical affections
Malar rashes 59%
Discoid rashes 21%
Photosensitivity 72%
Ulcers 41%
Arthritis 63%
Renal involvement 47%
Lung involvement 18%
Cardiac involvement 16%
Neurological alterations 28%
Haematological alterations 54%
Immunological alterations 86%
Anti-phospholipid syndrome 15%
Secondary Sj€ogren’s syndrome 12%
Therapy
Glucocorticoids 69%
Glucocorticoid dosages
(mg prednisone eq.)
Median: 55;
range: 125–50
Antimalarials 68%
Azathioprine 21%
Methotrexate 3%
Mycophenolate mofetil 13%
Cyclosporin A 1%
Oral steroids 21%
2. Unaffected 1st-degree relatives Total: 194
Gender Male: 39%; female: 61%
Age Median: 485 years;
range: 18–86 years
3. Unrelated healthy controls Total: 141
Gender Male: 48%;
female: 52%
Age Median: 44 years;
range: 20–68 years
SLE 5 systemic lupus erythematosus; SLEDAI 5 SLE Disease
Activity Index.
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Fig. 1. Regulatory T cell (Tregs) subset gating. The figure shows our cytometric gating of CD4
1 T cell subsets. Apart from the conventional
forkhead box P3 (FoxP3)– (naive and memory) T helper (Th), FoxP31 Tregs were divided into three subsets using FoxP3 and CD45RO staining.
Two examples are depicted with their T helper (Th) and Tregs subset frequencies within CD4
1 cells: (a) a healthy control subject; (b) a systemic
lupus erythematosus (SLE) patient. Irrespective of differences in absolute staining intensities, the distance between the lower boundaries of
FoxP3l8w and activated Tregs was kept constant throughout all samples. Parallel CD127 staining (not shown) was not used for gating but for
quality control.
Fig. 2. Surface CD25 in Treg subsets. Quantitative surface CD25 distributions and group differences for (a) all CD4
1forkhead box P3 (FoxP3)1
cells, (b) naive regulatory T cells (Tregs), (b) activated Tregs and (d) FoxP3
low cells. Significant P-values are shown; n.s. 5 non-significant.
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and particularly did not directly compare patients and rela-
tives, which were drawn from the same families and cannot
be compared irrespective of their familial relations with
adequate statistical power. Relations between continuous
variables (including genotypes) were characterized by linear
correlation coefficients (sometimes partial or semipartial)
and tested by linear regression analysis. Multiple linear
regression was used to consider covariates. For genetic asso-
ciation, univariate P-values were corrected for multiple com-
parisons (i.e. the 25 SNPs tested) with the Benjamini–
Hochberg false discovery rate (FDR) method. P-values below
005 were considered statistically significant.
Results
CD25 reduction on SLE Tregs is shared by the
patients’ first-degree relatives
Comparing quantitative CD25 surface staining intensities
in 45 SLE patients, 103 unaffected relatives and 61
unrelated healthy controls, we found CD25 MFI impres-
sively reduced in patients versus controls not only when
considering all FoxP31 cells (Fig. 2a), but also within each
of their three subsets (depicted in Fig. 1) defined by Miyara
et al. [30]: naive (Fig. 2b) and activated (Fig. 2c) Tregs, as
well as FoxP3low cells (Fig. 2d). Patients’ median CD25 was
reduced 17-fold in total FoxP31, 16 and 17-fold in naive
and activated Tregs, respectively, and 14-fold in FoxP3low
cells. This subset-overarching CD25 deficiency was shared
remarkably by the unaffected first-degree relatives, where
CD25 densities were also significantly lower in all
CD41FoxP31 subpopulations than in controls (14-fold in
total FoxP31 and 13-fold in all three subsets), while still
higher than in the patients. The intermediate position of
the unaffected relatives points to shared heritable factors
and therefore supports Treg CD25 as a pathogenesis-related
biomarker. Approximations of cell proportions lacking sur-
face CD25 (although based on an arbitrary threshold defi-
nition) mirror the MFI characteristics (Supporting
information, Fig. S1).
Fig. 3. Characteristics of surface CD25 levels of recent thymic emigrant (RTE) Tregs. (a) Reduction of RTE regulatory T cells (Tregs) CD25 in
systemic lupus erythematosus (SLE) patients and in unaffected relatives versus control subjects. (b,c) Significant correlation of RTE Treg CD25
with proportions of interleukin (IL)-2 producers among phorbol myristate acetate (PMA)/I-stimulated memory T cells in SLE patients and
controls (while insignificant in unaffected relatives, not shown). (d–f) Significant correlations of RTE Treg CD25 with activated Treg frequencies in
patients and relatives, but not control subjects. Linear correlation coefficients (R) and significant P-values are shown; n.s. 5 non-significant.
N. Costa et al.
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Subsetwise CD25 levels were particularly interesting. We
found that surface CD25 MFIs of the naive and activated
Treg subsets were statistically independent from other meas-
ures obtained for the respective subset, i.e. CD25 was never
significantly correlated with the same subset’s circulating
numbers, frequencies within total FoxP31 or CD41 cells,
or Ki671 proliferating fractions in any of our three study
groups (not shown). There were also no significant rela-
tions to patients’ SLE Disease Activity Index (SLEDAI)-2k
disease activity, other clinical characteristics or treatments
(Table 1) or to gender or age, except for a marginal
R5 02/P5 0046 age correlation with naive Treg CD25
only within unaffected relatives.
Although uncorrelated with surface CD25, circulating
Treg numbers were also decreased both in patients and rela-
tives, but less significantly (Supporting information, Fig.
S2). In terms of Treg subset numbers per blood volume this
was, however, restricted to the activated Tregs, which alone
accounted for the differences in total FoxP31 cells while
naive Treg and FoxP3
low numbers did not differ between
groups (Supporting information, Fig. S2, first column).
Relatively counted within total FoxP31 cells (Supporting
information, Fig. S2, second column), FoxP3low cells
replaced the activated Tregs. Only when calculated within
total CD41 cells (Supporting information, Fig. S2, third
column), Treg subset characteristics were no longer shared
by patients and relatives – an effect that can, in fact, be
explained by a relative over-representation of Tregs in SLE
patients with lymphopenia and that disappeared when only
non-lymphopenic subjects were considered (Supporting
information, Fig. S3).
Effect 1: characteristic and functionally relevant
CD25 reduction already in CD311 recent thymic
emigrant Tregs
Like naive Th cells, naive Tregs also contain a subpopulation
of recent thymic emigrants (RTE), which can be distin-
guished as the developmentally earliest Tregs by their CD31
expression [39]. We studied RTE Tregs with specific empha-
sis and found that their surface CD25 was already reduced
strongly, actually showing almost identically low levels in
SLE patients and unaffected relatives (15 and 14-fold
reduced, respectively) compared to healthy controls
(Fig. 3a, mirrored by CD25– approximations within RTE
Tregs; see Supporting information, Fig. S1).
As human Treg development involves IL-2-driven intra-
thymic CD25 induction [40], we asked whether CD25
expression by RTE Tregs depended upon the individual
capacity to produce IL-2. The CD25 MFI of RTE Tregs was
indeed found to be correlated positively with the capacity
of cultured CD31CD45RO1 T memory cells to produce IL-
2 upon PMA/ionomycin stimulation in SLE patients and
also in controls (Fig. 3b,c; for IL-2 stainings, for example,
see Supporting information, Fig. S4). By contrast, RTE Treg
CD25 levels were unrelated to patients’ SLEDAI-2k disease
Fig. 4. CD25 up-regulation in activated regulatory T cells (Tregs) is selectively impaired in systemic lupus erythematosus (SLE) patients. (a)
Individual trajectories of CD25 levels through the three Treg differentiation stages (thin lines) and their groupwise averages (thick lines). Reduced
CD25 in naive Treg subsets appears ‘compensated’ in unaffected relatives but not in SLE patients by a subset-specific up-regulation in activated
Tregs. (b) Quantified as CD25 mean fluorescence intensity (MFI) difference between naive and activated Tregs; this up-regulation was equal in
relatives and controls, but significantly lower in the SLE patients. The P-value is shown; n.s. 5 non-significant.
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activity, other clinical characteristics and treatment (Table
1) and to gender and age in all groups, except for a mar-
ginal increase with age within unaffected relatives,
R5 025/P5 002 (not shown).
RTE Treg CD25 levels were also completely unrelated to
their highly age-dependent and barely group-characteristic
circulating numbers and frequencies (Supporting informa-
tion, Fig. S5), as well as to Ki671 proliferating fractions
(not shown). Instead, we detected a remarkably strong cor-
relation to proportions of activated among total Tregs in
patients (R5 053/P5 3E-4) as well as in unaffected rela-
tives (R5 042/P5 2E-5) (Fig. 3d–f). These activated Treg
proportions were found to be correlated far less with CD25
levels when measured on all naive Tregs [patients: R5 029/
not significant (n.s.); relatives: R5 032/P5 0001], and
completely unrelated to CD25 levels of the activated Tregs
themselves. This suggests that the RTE Treg surface CD25
levels uniquely indicate the conditioning effect that the
state of early Tregs appears to have on the individual
capacity in our SLE risk population to produce high num-
bers of fully activated peripheral Tregs.
Effect 2: CD25 up-regulation in activated versus naive
Tregs is specifically deficient in manifest SLE
As activated Tregs are derived largely from naive Tregs
[30,31] but generally show higher surface CD25 levels, we
addressed specifically their capacity to up-regulate CD25
when differentiating from naive Tregs, measured as the MFI
difference between both subsets in the same subject. While
Fig. 5. Characteristics of surface CD25
up-regulation levels by activated
regulatory T cells (Tregs). (a,b) CD25 up-
regulation correlates with proportions of
interleukin (IL)-2-producing T memory
cells upon phorbol myristate acetate/
ionomycin (PMA/I) stimulation in
systemic lupus erythematosus (SLE)
patients but not in relatives or controls.
(c,d) CD25 up-regulation correlates with
reduced naive Tregs relative to naive
conventional T helper (Th) cells in SLE
patients but not in relatives or controls.
(e,f) CD25 up-regulation correlates with
Ki671 proliferating fractions of activated
Tregs in SLE patients and relatives but not
in controls. (b,d,f) Circles and full
regression lines indicate unaffected
relatives; triangles and pointed lines
indicate unrelated controls. Linear
correlation coefficients (R) and significant
P-values are shown; n.s. 5 non-
significant.
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there was no significant difference between unaffected rela-
tives and controls, CD25 up-regulation was significantly
lower and almost absent in SLE patients (Fig. 4). Thus,
unaffected relatives of SLE patients appeared able to up-
regulate CD25 in activated Tregs to the same extent as
healthy controls, while SLE patients had a specific defi-
ciency in this respect.
The SLE patients’ CD25 up-regulation in activated versus
naive Tregs was also found to be correlated positively with
the individual capacity of their T memory cells to produce
IL-2 upon PMA/ionomycin stimulation (Fig. 5a), as was
CD25 in RTE Tregs. In contrast, no such correlation was
found in unaffected relatives or controls (Fig. 5b), indicat-
ing that the IL-2 dependency of CD25 up-regulation was
limited to SLE patients where it was also particularly
defective.
CD25 up-regulation in activated Tregs was uncorrelated
with RTE Treg CD25 levels (effect 1) in relatives and in con-
trol subjects, and a positive correlation of both within
patients was due entirely to their shared IL-2 dependency
(Supporting information, Fig. S6). We also detected no sig-
nificant relations to age, gender, SLEDAI-2k disease activ-
ity, clinical characteristics or treatment (not shown). Thus,
CD25 up-regulation fulfills all criteria of being an
independent second effect contributing to the SLE-
associated Treg defect, reflecting peripheral but not thymic
influences on Treg CD25 expression.
While CD25 up-regulation in activated Tregs was basi-
cally uncorrelated with numbers and frequencies of acti-
vated Tregs, there were negative correlations with naive Tregs
(Supporting information, Fig. S7). Interpreted as precursor
consumption accompanying Treg activation, this could par-
ticularly explain that among patients, those with virtually
absent CD25 up-regulation were paradoxically the ones
with most naive Tregs also in relation to naive FoxP3
– T
helpers (Fig. 5c,d). Furthermore, in the patients and rela-
tives groups, CD25 up-regulation was correlated positively
with Ki671 fractions within activated Tregs (Fig. 5e,f) sug-
gesting that, apart from recruitment, their proliferation
also influences this property.
Effect 1 shows the strongest heritability, and effect 2
is associated to IL2RA (CD25) genetic variants
In order to estimate overall genetic effects on the two
described effects contributing to Treg CD25 deficiency in
SLE, we addressed their probable heritability within our
affected families by assessing familial correlations. Both
Table 2. Genetic associations with polymorphisms in the IL2RA locus in control subjects
SNP
Position
(Chr.10) Alleles
Association with effect 1 Association with effect 2 Allele
assoc. with
low CD25
Allele assoc.
with T1D§R* P† PFDR‡ R* P† PFDR‡
rs12359875 6009144 CT 004 07438 032 00129 00647
rs12244380 6011411 AG 2001 09204 2002 08863
rs9663421 6013641 CT 016 02213 021 01030
rs2076846 6021290 AG 2018 01736 003 08338
rs11256369 6024237 CG 2018 01654 2010 04211
rs7072398 6037883 AG 2019 01534 2020 01189
rs4749924 6040433 AC 008 05316 020 01275
rs706781 6044422 CT 010 04586 2012 03728
rs11256497 6045831 AG 2014 02860 2028 00283 01010
rs791587 6046736 AG 2004 07653 2009 04823
rs791589 6047608 AG 004 07891 2026 00506
rs10905669 6050130 CT 002 08787 2001 09635
rs2256774 6055202 CT 2030 00191 02384 2034 00079 00656
rs706779 6056861 CT 2035 00056 01409 2033 00112 00701
rs706778 6056986 CT 2014 02805 2020 01375
rs2104286 6057082 CT 006 06458 013 03368
rs7072793 6064303 CT 014 02743 019 01443
rs7073236 6064589 CT 014 02743 019 01443
rs11597367 6065571 AG 011 03804 037 00035 00434 A A
rs10795791 6066377 AG 2014 02743 2019 01443
rs4147359 6066476 AG 001 09360 007 05913
rs7090530 6068912 AC 019 01322 029 00228 00948
rs41295061 6072697 AC 2001 09393 002 08867
rs11594656 6080046 AT 2011 03804 2037 00035 00434 T T
rs12251307 6081532 CT 005 07050 2001 09630
*Linear correlation coefficient. †P-values from univariate regression (significant values < 005 in bold type). ‡P-values false-positive discovery
rate (FDR)-corrected for multiple comparisons (significant values < 005 in bold type). §According to Lowe et al. [41].
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parental and sibling correlations were indeed found highly
significant for effect 1, RTE Treg CD25 (qP 5 073/P5 2E-
12; qS 5 070/P5 5E-8), indicating a high heritability. For
effect 2, CD25 MFI up-regulation, familial correlations
were clearly lower but still significant (qP 5 044/P5 1E-
5; qS 5 027/P5 0032).
In our control group, where subjects were unrelated, we
finally studied whether the two component effects were asso-
ciated with genetic variation in the IL2RA locus that encodes
CD25. For effect 1, RTE Treg CD25, association with two of
25 typed SNPs was univariately significant but did not retain
significance upon FDR correction for multiple comparisons
(Table 2). In contrast, IL2RA SNP association with effect 2,
CD25 MFI up-regulation, was significant also when FDR-
corrected. The associated SNPs were located in the IL2RA 5’
portion (Table 2), corresponding to the region where genetic
association primarily with type 1 diabetes (T1D) was also
reported. In fact, the two SNP alleles that we found associ-
ated significantly with reduced CD25 up-regulation were
also described as T1D risk alleles [41].
Discussion
In SLE Tregs, a particular surface CD25 reduction ‘dissoci-
ated’ from FoxP3 expression was described previously [25],
while the details and origins of this reduction have not
been assessed thoroughly. Studying CD25 in Treg subsets,
we could discriminate two independent effects contributing
to the reduced surface CD25 in SLE that were both related
to individual IL-2 production:
 effect 1, surface CD25 of the developmentally earliest
RTE Tregs, was reduced in both SLE patients and unaf-
fected relatives in a largely shared manner; and
 effect 2, the degree to which Tregs up-regulated CD25
upon activation, was only deficient in manifest SLE
but not in unaffected relatives. This CD25 up-
regulation was associated (in controls) with IL2RA
genetic variants.
Effect 1 – RTE Treg surface CD25 – likely reflects intra-
thymic Treg development [40]. It neither depended upon
disease manifestation nor did it correlate with disease activ-
ity. It was also unrelated to the age-dependent RTE Treg
numbers and frequencies, but highly heritable, as suggested
by familial correlations. Thus, RTE Treg CD25 clearly does
not represent an effect secondary to clinical disease, treat-
ment or age, but rather a primary, largely genetically deter-
mined and individually variable ‘baseline’ CD25 that seems
to be set intrathymically, as it is best visible in the develop-
mentally earliest Tregs. Most interestingly, RTE Treg CD25
(unlike surface CD25 of activated or overall naive Tregs)
was correlated uniquely positively, thus predictive for
peripheral proportions of fully differentiated activated Tregs
in the individual patients and relatives. This suggests that
the RTE Treg functional state reflected by their surface
CD25 level is crucial for the capacity of subjects at risk for
SLE to produce high proportions of activated peripheral
Tregs.
Effect 2 – CD25 up-regulation in activated versus na€ıve
Tregs – demonstrates a specific failure of SLE Tregs to
increase CD25 expression when differentiating into acti-
vated CD45RO1 Tregs in the periphery. This failure was not
seen in first-degree unaffected relatives and therefore
appears secondary to SLE manifestation (although we
observed no relation to clinical features or treatment).
Coincident with our earlier report pointing to a compensa-
tory T cell regulation [37], it can be said that unaffected
relatives ‘compensate’ their shared baseline CD25 reduction
in early non-activated Tregs (effect 1) by activation-
dependent up-regulation – a mechanism that could be
important for subjects at risk to avoid clinical disease.
Unlike effect 1, effect 2 was not associated with increased
activated Treg quantities in circulation, while it was related
to naive Treg consumption and to activated Treg prolifera-
tion. This can be explained by the short-lived nature of
activated Tregs [30].
Technically, our quantitation of CD25 up-regulation
(effect 2) is based upon the assumption of a common Treg
lineage, i.e. that transient FoxP3 expression and peripher-
ally induced Tregs do not need to be considered. This seems
reasonable to us in this context, as SLE Foxp31 Tregs,
including CD25low and CD25– cells, have shown extraordi-
narily high levels of Helios expression and FoxP3–TSDR
demethylation [7,32]. While Helios expression indicates a
thymic origin [33,34], cytosine–phosphate–guanine (CpG)
demethylation of the FoxP3–TSDR region [35] confirms
sustained bona-fide FoxP3 expression. Both markers do
not occur in transiently FoxP3-expressing T helpers or
induced Tregs. Moreover, FoxP3
low cells where transient
expression may occur were excluded thoroughly from our
cytometric definition of activated Tregs.
Our findings add to a series of papers which showed
neatly that surface CD25 (but not FoxP3) is the only
marker that can reflect the SLE-associated phenotypical
[21,28] and functional [25,28] Treg impairment appropri-
ately. The two effects acting on reduced Treg CD25 expres-
sion described by us here were both related to the capacity
of effector cells to produce its ligand, IL-2, which is recog-
nized widely as the most important factor for Treg homeo-
stasis, since the time when it was first demonstrated that
IL-2-deficient mice harbour very few Tregs with low surface
CD25 [42]. The crucial role of IL-2, particularly for periph-
eral Treg maintenance and expansion, is also generally
accepted for the human system [43], and we have recently
described its effects particularly in respect to SLE-
associated autoantibody profiles [37]. More recently, IL-2
was shown to be similarly important (besides IL-15) for
the thymic generation of human Tregs [40]. Particularly in
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SLE, T cells obviously produce insufficient amounts of IL-2
due to altered transcriptional regulation [4]. Accordingly, a
recent report demonstrates that the CD25 deficiency of
SLE Tregs could be reversed efficiently by IL-2 in cell cul-
tures, as well as in patients undergoing low-dose IL-2 ther-
apy [7]. This corresponds with findings that restoring IL-2
production in lupus-prone mice enhanced the generation
of CD251FoxP31 Tregs [44,45].
Our results suggest that deficient IL-2 in SLE affects sur-
face CD25 in two separate ways in early and in late Tregs.
Both effects appear genetically influenced. While the early
effect 1 showed indirect evidence of (unspecified) genetic
factors, the patient-characteristic late effect 2 was found
associated with genetic variants in the region of the CD25-
encoding locus IL2RA that also conferred T1D risk [41].
Located 5’ upstream of the IL2RA locus, the effect linked to
these variants is unlikely to alter CD25 molecular proper-
ties, but rather transcriptional control by (not well known)
transcription factors [46]. Among the different haplotypes
that have meanwhile been identified in this region [41,47],
our findings point mainly to a functionally unexplored
rs11594656 haplotype where, conversely, T1D risk variants
protected from multiple sclerosis (MS) [48]. For the better-
studied rs2104286 haplotype in the same region, healthy
individuals bearing the risk variant for both diseases with
low IL-2 receptor signalling [49] also had fewer Tregs with
reduced suppressive function and less stable FoxP3 expres-
sion under limiting IL-2 concentrations [50]. Loss of
FoxP3 expression by Tregs in IL-2 insufficient conditions is
also well documented from mouse experiments [51,52]
and explained by IL-2 mediated transcriptional stabiliza-
tion [53]. Ex-Tregs convert typically into Th17 cells, can eas-
ily become pathogenic and cause lung and liver
inflammation [51], arthritis [54] and autoantigen-driven
encephalitis [55]. Also in human MS, IL-2–IL2R pathway
alterations were linked to decreased FoxP3 expression [56],
and Tregs converting to Th17 cells probably contribute to
human inflammatory bowel diseases [57], rheumatoid
arthritis [58] and psoriasis [59] by shifting the paradig-
matic balance between these two developmentally related
cell types [60]. As the relevance of this for SLE remains
somewhat unclear, our discrimination of two separate
component effects may help to characterize further how
the probably multiple associated mechanisms affect each
type of autoimmunity.
In SLE patients, defective CD25 expression by Tregs was
found completely reversible under low-dose IL-2 therapy
[7]. In our context, this corresponds most probably to a
boost of effect 2, most affected in SLE patients and in fact
showing less overall genetic determination (i.e. heritabil-
ity), thus a more ‘acquired’ character, than effect 1. How-
ever, low-dose IL-2 therapy increased not only CD25
expression but even more impressively the numbers of cir-
culating FoxP31 Tregs. Interpreted in the context of our
results, this also points to the involvement of IL-2 effects
on non-activated Tregs, possibly even inside the thymus
analogously to our effect 1, in addition to peripheral stimu-
lation (effect 2). It will be extremely interesting to deter-
mine this in future clinical studies, as well as how the
clinical outcome relates to the two effect types, in order to
identify optimal therapy schemes for IL-2 and possibly
other therapies seeking to improve Treg function.
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Fig. S1. Approximation of regulatory T cell (Treg) propor-
tions lacking surface CD25. Although we are cautious
about threshold-defined CD25 gating and do not use it
for our own quantitative analysis, we have approximated
proportions of CD25– cells within Tregs by a plausible but
still arbitrary threshold criterion (fluorescence intensity
< 5) for comparability with other published work. (a,b)
CD25– cells within naive Tregs, separately for CD31
1
(recent thymic emigrants) and CD31–, (c) within acti-
vated Tregs and (d) within all CD4
1 forkhead box P3
(FoxP3)1 T cells. Group differences of patients or unaf-
fected relatives, respectively, to healthy unrelated control
subjects were tested. Significant P-values are shown.
Fig. S2. Group differences between regulatory T cell (Treg)
numbers and frequencies depend strongly upon the type
of measure. The three common measures of cell abun-
dance are shown comparatively in columns: circulating
cell numbers per blood volume (first column), frequen-
cies within total forkhead box P3 (FoxP3)1 cells (second
column) and frequencies within total CD41 T cells (third
column). Rows represent the three Treg subsets and total
FoxP31. For each measure, group differences of patients
or unaffected relatives, respectively, to healthy unrelated
control subjects were tested. Significant P-values are
shown; n.s. 5 non-significant.
Fig. S3. Lymphopenia effect on regulatory T cell (Treg)
frequencies when measured within CD41 cells. (a) Circu-
lating lymphocyte numbers per group demonstrate that
many systemic lupus erythematosus (SLE) patients (but
not unaffected relatives) have low lymphocyte numbers.
(b) forkhead box P3 (FoxP3)1 frequencies within total
CD41 cells correlated strongly with lymphocyte numbers,
showing their overrepresentation particularly in lympho-
penic SLE patients. This over-representation also caused a
distribution bias of Treg subset measures within CD4
1
cells: when only non-lymphopenic subjects were consid-
ered, the previously detected increase in patients’ naive
Tregs/CD4
1 was abrogated (c), and activated Treg differen-
ces corresponded to those found for absolute cell num-
bers (d). Linear correlation coefficients (R) and
significant P-values are shown; n.s. 5 non-significant.
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Fig. S4. Intracellular interleukin (IL)-2 staining examples.
Gated on CD31CD45RO1 memory T cells, representative
cytograms for intracellular IL-2 [vertically versus horizon-
tal interferon (IFN)-g] staining are shown for (a) a sys-
temic lupus erythematosus (SLE) patient, (b) a first-
degree relative, (c) an unrelated healthy control and (d)
without anti-IL-2 antibody. Percentages of IL-2 positive
cells are annotated.
Fig. S5. Characteristics of different measures of recent
thymic emigrants (RTE) regulatory T cell (Treg) numbers
and frequencies. (a–d) Four different measures of RTE
Tregs were analysed for their relation to age and groups.
All measures showed a significant decrease with age in all
three groups. Accordingly, group comparisons were calcu-
lated with age as a covariate. None of the four measures
showed a significant difference between relatives and con-
trols. Patients had significant reductions in absolute num-
bers (a) and frequencies within naive Tregs (d) but not
when measured within total forkhead box P3 (FoxP3)1
(b) or CD41 (b). (e,f) Relations of RTE Treg measures to
RTE Treg surface CD25. No significant relations were
found, as all groupwise direct or semipartial correlations
(numbers/frequencies regressed against age) were found
univariately insignificant.
Fig. S6. The correlation between recent thymic emigrants
(RTE) regulatory T cell (Treg) CD25 and CD25 up-
regulation in activated Tregs is due entirely to their shared
interleukin (IL)-2 dependency. (a) The direct correlation
between the two CD25 component effects was found sig-
nificant only for patients but not relatives or controls. (b)
As both CD25 component effects depended upon IL-2
producers in patients, we further calculated their partial
correlation (i.e. of both regressed against our measures of
IL-2 producer proportions). The absence of significance
demonstrates that the previously detected correlation was
due to an IL-2 effect. Linear correlation coefficients (R)
and significant P-values are shown; n.s. 5 non-significant.
Fig. S7. Relations of CD25 up-regulation in activated reg-
ulatory T cells (Tregs) (effect 2) to Treg subset measures.
We studied the possible relation of CD25 up-regulation
in activated Tregs (effect 2) to three common measures of
naive and activated Treg numbers and frequencies, respec-
tively (analogously to Fig. S2). (a–c) None of the acti-
vated Treg measures showed a significant relation when
assessed by multiple regression, differentiating the three
subject groups by two contrast covariates. Univariately,
only activated Tregs/CD4
1 measured within patients
showed a significant correlation (c) which was, however,
ascribable to lymphopenia bias as abrogated when consid-
ering only non-lymphopenic subjects analogously to Fig.
S3. (d–f) In contrast, all three measures of naive recent
thymic emigrants (RTE) regulatory T cell (Treg) numbers
or frequencies were found related significantly to decreas-
ing CD25 up-regulation in activated Tregs (effect 2) using
the same multiple regression approach. Univariate group-
wise correlation (although not significant throughout)
also remained significant with naive Tregs/CD4
1 in
patients when considering only non-lymphopenic patients
(f). Linear correlation coefficients (R) and significant P-
values are shown; n.s. 5 non-significant.
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